GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Nidan Laboratories and Healthcare Ltd (NSE:NIDAN) » Definitions » ROE %

Nidan Laboratories and Healthcare (NSE:NIDAN) ROE % : 3.53% (As of Mar. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Nidan Laboratories and Healthcare ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Nidan Laboratories and Healthcare's annualized net income for the quarter that ended in Mar. 2023 was ₹24.4 Mil. Nidan Laboratories and Healthcare's average Total Stockholders Equity over the quarter that ended in Mar. 2023 was ₹691.8 Mil. Therefore, Nidan Laboratories and Healthcare's annualized ROE % for the quarter that ended in Mar. 2023 was 3.53%.

The historical rank and industry rank for Nidan Laboratories and Healthcare's ROE % or its related term are showing as below:

NSE:NIDAN's ROE % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -1.93
* Ranked among companies with meaningful ROE % only.

Nidan Laboratories and Healthcare ROE % Historical Data

The historical data trend for Nidan Laboratories and Healthcare's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nidan Laboratories and Healthcare ROE % Chart

Nidan Laboratories and Healthcare Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
ROE %
Get a 7-Day Free Trial 6.70 18.90 6.72 5.23 -4.77

Nidan Laboratories and Healthcare Semi-Annual Data
Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Mar24
ROE % Get a 7-Day Free Trial 27.06 2.61 6.88 3.53 -

Competitive Comparison of Nidan Laboratories and Healthcare's ROE %

For the Diagnostics & Research subindustry, Nidan Laboratories and Healthcare's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nidan Laboratories and Healthcare's ROE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Nidan Laboratories and Healthcare's ROE % distribution charts can be found below:

* The bar in red indicates where Nidan Laboratories and Healthcare's ROE % falls into.


;
;

Nidan Laboratories and Healthcare ROE % Calculation

Nidan Laboratories and Healthcare's annualized ROE % for the fiscal year that ended in Mar. 2024 is calculated as

ROE %=Net Income (A: Mar. 2024 )/( (Total Stockholders Equity (A: Mar. 2023 )+Total Stockholders Equity (A: Mar. 2024 ))/ count )
=-32.323/( (694.384+662.061)/ 2 )
=-32.323/678.2225
=-4.77 %

Nidan Laboratories and Healthcare's annualized ROE % for the quarter that ended in Mar. 2023 is calculated as

ROE %=Net Income (Q: Mar. 2023 )/( (Total Stockholders Equity (Q: Sep. 2022 )+Total Stockholders Equity (Q: Mar. 2023 ))/ count )
=24.428/( (689.207+694.384)/ 2 )
=24.428/691.7955
=3.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Mar. 2023) net income data. ROE % is displayed in the 30-year financial page.


Nidan Laboratories and Healthcare  (NSE:NIDAN) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2023 )
=Net Income/Total Stockholders Equity
=24.428/691.7955
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(24.428 / 203.546)*(203.546 / 858.46)*(858.46 / 691.7955)
=Net Margin %*Asset Turnover*Equity Multiplier
=12 %*0.2371*1.2409
=ROA %*Equity Multiplier
=2.85 %*1.2409
=3.53 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2023 )
=Net Income/Total Stockholders Equity
=24.428/691.7955
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (24.428 / 35.796) * (35.796 / 2.7) * (2.7 / 203.546) * (203.546 / 858.46) * (858.46 / 691.7955)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.6824 * 13.2578 * 1.33 % * 0.2371 * 1.2409
=3.53 %

Note: The net income data used here is two times the semi-annual (Mar. 2023) net income data. The Revenue data used here is two times the semi-annual (Mar. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Nidan Laboratories and Healthcare ROE % Related Terms

Thank you for viewing the detailed overview of Nidan Laboratories and Healthcare's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nidan Laboratories and Healthcare Business Description

Traded in Other Exchanges
N/A
Address
Vartak Road, SY No. 294/A H. No. 18, Swapnshilpa Bunglow, Behind Aarti Apartment, Virar West, Palghar, Virar, MH, IND, 401303
Nidan Laboratories and Healthcare Ltd offer diagnostic services including radiology, neurology, cardiology, dental as well as pathology services. The company provides pathology tests ranging from basic biochemistry and clinical pathology to cytogenetic and high-end molecular diagnostic tests, and radiology tests ranging from basic echocardiograms, X-Rays, and ultrasounds to radiology tests including computerized tomography scans, magnetic resonance imaging scans.

Nidan Laboratories and Healthcare Headlines

No Headlines